Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biomolecules ; 11(8)2021 07 30.
Article in English | MEDLINE | ID: mdl-34439791

ABSTRACT

CHO is the cell line of choice for the manufacturing of many complex biotherapeutics. The constant upgrading of cell productivity is needed to meet the growing demand for these life-saving drugs. Manipulation of small non-coding RNAs-miRNAs-is a good alternative to a single gene knockdown approach due to their post-transcriptional regulation of entire cellular pathways without posing translational burden to the production cell. In this study, we performed a high-throughput screening of 2042-human miRNAs and identified several candidates able to increase cell-specific and overall production of Erythropoietin and Etanercept in CHO cells. Some of these human miRNAs have not been found in Chinese hamster cells and yet were still effective in them. We identified miR-574-3p as being able, when overexpressed in CHO cells, to improve overall productivity of Erythropoietin and Etanercept titers from 1.3 to up to 2-fold. In addition, we validated several targets of miR-574-3p and identified p300 as a main target of miR-574-3p in CHO cells. Furthermore, we demonstrated that stable CHO cell overexpressing miRNAs from endogenous CHO pri-miRNA sequences outperform the cells with human pri-miRNA sequences. Our findings highlight the importance of flanking genomic sequences, and their secondary structure features, on pri-miRNA processing offering a novel, cost-effective and fast strategy as a valuable tool for efficient miRNAs engineering in CHO cells.


Subject(s)
Erythropoietin/genetics , Etanercept/metabolism , Genetic Engineering/methods , MicroRNAs/genetics , Transgenes , Animals , CHO Cells , Cricetulus , E1A-Associated p300 Protein/genetics , E1A-Associated p300 Protein/metabolism , Erythropoietin/biosynthesis , Etanercept/chemistry , Gene Expression Regulation , High-Throughput Screening Assays , Humans , MicroRNAs/metabolism , Nucleic Acid Conformation , Recombinant Proteins/biosynthesis , Recombinant Proteins/genetics , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism
2.
Nucleic Acids Res ; 42(5): 3362-71, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24369426

ABSTRACT

TDP-43 is a nuclear protein involved in many aspects of RNA metabolism. To ensure cellular viability, its expression levels within cells must be tightly regulated. We have previously demonstrated that TDP-43 autoregulation occurs through the activation of a normally silent intron in its 3'-UTR sequence that results in the use of alternative polyadenylation sites. In this work, we analyse which is the dominant event in autoregulation: the recognition of the splice sites of 3'-UTR intron 7 or the intrinsic quality of the alternative polyadenylation sites. A panel of minigene constructs was tested for autoregulation functionality, protein production and subcellular messenger RNA localization. Our data clearly indicate that constitutive spliceosome complex formation across intron 7 does not lead to high protein production but, on the contrary, to lower TDP-43 messenger RNA and protein levels. This is due to altered nucleocytoplasmic distribution of the RNA that is mostly retained in the nucleus and degraded. This study provides a novel in-depth characterization of how RNA binding proteins can autoregulate their own levels within cells, an essential regulatory process in maintaining cellular viability.


Subject(s)
DNA-Binding Proteins/genetics , Polyadenylation , RNA Splicing , RNA-Binding Proteins/genetics , Cell Nucleus/metabolism , Cytoplasm/metabolism , DNA-Binding Proteins/metabolism , HEK293 Cells , Homeostasis , Humans , Introns , RNA Splice Sites , RNA Transport , RNA, Messenger/metabolism , RNA-Binding Proteins/metabolism , Spliceosomes/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL